156 related articles for article (PubMed ID: 19890087)
1. Microbial contamination of syringes during preparation: the direct influence of environmental cleanliness and risk manipulations on end-product quality.
Stucki C; Sautter AM; Favet J; Bonnabry P
Am J Health Syst Pharm; 2009 Nov; 66(22):2032-6. PubMed ID: 19890087
[TBL] [Abstract][Full Text] [Related]
2. Parenterals laboratory course to reduce microbial contamination rates in media fill tests performed by pharmacy students.
Isanhart CM; McCall KL; Kretschmer D; Grimes BA
Am J Pharm Educ; 2008 Apr; 72(2):27. PubMed ID: 18483595
[TBL] [Abstract][Full Text] [Related]
3. Potential for airborne contamination in turbulent- and unidirectional-airflow compounding aseptic isolators.
Peters GF; McKeon MR; Weiss WT
Am J Health Syst Pharm; 2007 Mar; 64(6):622-31. PubMed ID: 17353571
[TBL] [Abstract][Full Text] [Related]
4. Effect of two work practice changes on the microbial contamination rates of pharmacy-compounded sterile preparations.
Trissel LA; Gentempo JA; Saenz LM; Woodard MY; Angeles CH
Am J Health Syst Pharm; 2007 Apr; 64(8):837-41. PubMed ID: 17420200
[TBL] [Abstract][Full Text] [Related]
5. Control of the aseptic processing environment.
Frieben WR
Am J Hosp Pharm; 1983 Nov; 40(11):1928-35. PubMed ID: 6650522
[TBL] [Abstract][Full Text] [Related]
6. Using medium-fill simulation to establish a benchmark microbiological contamination rate for low-risk-level compounding.
Trissel LA; Ogundele AB; Ingram DS; Saenz CA; Gentempo JA
Am J Health Syst Pharm; 2003 Sep; 60(18):1853-5. PubMed ID: 14521036
[TBL] [Abstract][Full Text] [Related]
7. I.V. admixture contamination rates: traditional practice site versus a class 1000 cleanroom.
Thomas M; Sanborn MD; Couldry R
Am J Health Syst Pharm; 2005 Nov; 62(22):2386-92. PubMed ID: 16278330
[TBL] [Abstract][Full Text] [Related]
8. Impact of United States Pharmacopeia chapter 797: results of a national survey.
Candy TA; Schneider PJ; Pedersen CA
Am J Health Syst Pharm; 2006 Jul; 63(14):1336-43. PubMed ID: 16809754
[TBL] [Abstract][Full Text] [Related]
9. Potential for microbial contamination of ADD-Vantage admixtures.
Hudson TJ; Ambroziak EM; Coley RM
J Pharm Technol; 1992; 8(5):195-7. PubMed ID: 10121013
[TBL] [Abstract][Full Text] [Related]
10. Blueprint for implementing USP chapter 797 for compounding sterile preparations.
Kastango ES;
Am J Health Syst Pharm; 2005 Jun; 62(12):1271-88. PubMed ID: 15947127
[TBL] [Abstract][Full Text] [Related]
11. USP chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy.
Kastango ES; Bradshaw BD
Am J Health Syst Pharm; 2004 Sep; 61(18):1928-38. PubMed ID: 15487884
[No Abstract] [Full Text] [Related]
12. Microbial contamination potential of solutions in prefilled disposable syringes used with a syringe pump.
Mitrano FP; Baptista RJ; Newton DW; Augustine SC
Am J Hosp Pharm; 1986 Jan; 43(1):78-80. PubMed ID: 3953587
[TBL] [Abstract][Full Text] [Related]
13. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
Hung JC
J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
[No Abstract] [Full Text] [Related]
14. Antibiotic preparation time in a horizontal laminar-airflow hood and in a biological-safety cabinet.
Hamm JL; Daniels CE; Somani SM
Am J Hosp Pharm; 1984 Jul; 41(7):1349-51. PubMed ID: 6465149
[TBL] [Abstract][Full Text] [Related]
15. Does your pharmacy have a compounding isolator?
LaBella CJ
Am J Health Syst Pharm; 2007 Apr; 64(8):855-8. PubMed ID: 17420203
[No Abstract] [Full Text] [Related]
16. Evaluation of two sterility testing methods for intravenous admixtures.
Condella F; Eichelberger K; Foote LC; Griffin RE
Hosp Pharm; 1980 Jun; 15(6):305-10. PubMed ID: 10247270
[TBL] [Abstract][Full Text] [Related]
17. Sterility of filgrastim (G-CSF) in syringes.
Jacobson PA; West NJ; Spadoni V; Maksym CJ; Pierson C
Ann Pharmacother; 1996 Nov; 30(11):1238-42. PubMed ID: 8913403
[TBL] [Abstract][Full Text] [Related]
18. Titrated intravenous opioids from the same syringe: an infection risk?
Taylor M; Bourke J; Anderson M; Davey R; Kelly AM; Guthrie B
J Accid Emerg Med; 1997 Jan; 14(1):33-5. PubMed ID: 9023621
[TBL] [Abstract][Full Text] [Related]
19. The potential impact of USP 797 and what the JCAAI is doing about it.
Nathan R
Allergy Asthma Proc; 2007; 28(2):236-7. PubMed ID: 17479611
[No Abstract] [Full Text] [Related]
20. USP general chapter <797> pharmaceutical compounding-sterile preparations.
Hung JC
J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
[No Abstract] [Full Text] [Related]
[Next] [New Search]
